Literature DB >> 3297736

Limiting dilution assay for human B cells based on their activation by mutant EL4 thymoma cells: total and antimalaria responder B cell frequencies.

L Wen, M Hanvanich, C Werner-Favre, N Brouwers, L H Perrin, R H Zubler.   

Abstract

The analysis of human B cell responses at the clonal level (limiting dilution assay) is still technically difficult. In the present study we report on a culture system that leads to activation, proliferation and differentiation into antibody-secreting cells (ASC) of about 90% of B cells from peripheral blood or spleen. In this system, B cells are cultured in the presence of a mutant subclone of the mouse thymoma EL4 for B cell activation and human T cell plus macrophage supernatant as source of proliferation and differentiation factors. ASC precursors generating clonal responses of IgM only, IgM plus IgG, or IgG only occurred at a ratio of about 6:3:1. The mean clone size was 380 cytoplasmic Ig+ cells; the mean amount of Ig secreted per clone was 20 ng. Furthermore, it has been found using this system that a considerable proportion of peripheral blood B cells from individuals with a history of malaria infection could generate clones of anti-malaria (Plasmodium falciparum) ASC (range of 0.1 to 1%, n = 6). In a control group of blood donors the corresponding frequencies were 10 times lower (range of 0.01 to 0.1%, n = 9). These results show that the EL4 culture system can be applied to the investigation of the human B cell specificity repertoire and of priming effects such as result from infectious disease.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3297736     DOI: 10.1002/eji.1830170624

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  22 in total

1.  Signals sustaining human immunoglobulin V gene hypermutation in isolated germinal centre B cells.

Authors:  K Dahlenborg; J D Pound; J Gordon; C A Borrebaeck; R Carlsson
Journal:  Immunology       Date:  2000-10       Impact factor: 7.397

2.  Determination of the frequency of HLA antibody secreting B-lymphocytes in alloantigen sensitized individuals.

Authors:  A Mulder; M J Kardol; J Kamp; C Uit Het Broek; G M Schreuder; I I Doxiadis; F H Claas
Journal:  Clin Exp Immunol       Date:  2001-04       Impact factor: 4.330

Review 3.  Human B lymphocytes mature.

Authors:  J Gordon
Journal:  Clin Exp Immunol       Date:  1991-06       Impact factor: 4.330

Review 4.  Accessing the human repertoire for broadly neutralizing HIV antibodies.

Authors:  Philip W Hammond
Journal:  MAbs       Date:  2010 Mar-Apr       Impact factor: 5.857

Review 5.  Mining human antibody repertoires.

Authors:  Roger R Beerli; Christoph Rader
Journal:  MAbs       Date:  2010-07-01       Impact factor: 5.857

6.  Epstein-Barr virus transformation of Saimiri sciureus (squirrel monkey) B cells and generation of a Plasmodium brasilianum-specific monoclonal antibody in P. brasilianum-infected monkeys.

Authors:  C Chizzolini; A J Sulzer; M A Olsen-Rasmussen; W E Collins
Journal:  Infect Immun       Date:  1991-07       Impact factor: 3.441

7.  Frequencies of HIV-reactive B cells in seropositive and seronegative individuals.

Authors:  R H Zubler; L H Perrin; A Doucet; X Zhang; Y P Huang; P A Miescher
Journal:  Clin Exp Immunol       Date:  1992-01       Impact factor: 4.330

8.  CD40 plays an essential role in the activation of human B cells by murine EL4B5 cells.

Authors:  J Kwekkeboom; M De Boer; J M Tager; C De Groot
Journal:  Immunology       Date:  1993-07       Impact factor: 7.397

9.  The B cell repertoire of patients with rheumatoid arthritis. Frequencies and specificities of peripheral blood B cells reacting with human IgG, human collagens, a mycobacterial heat shock protein and other antigens.

Authors:  U Rudolphi; A Hohlbaum; B Lang; H H Peter; I Melchers
Journal:  Clin Exp Immunol       Date:  1993-06       Impact factor: 4.330

10.  Clonal dissection of the human memory B-cell repertoire following infection and vaccination.

Authors:  Debora Pinna; Davide Corti; David Jarrossay; Federica Sallusto; Antonio Lanzavecchia
Journal:  Eur J Immunol       Date:  2009-05       Impact factor: 5.532

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.